ࡱ;   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry  \pCalc Ba=J  !"#$%=@ 8X@"1Calibri1Arial1Arial1Arial1Calibri1Calibri General3._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_)!"($"#,##0_);[RED]"($"#,##0\) #,##0\(#,##0_);[RED]\(#,##0\) #,##0.00'""($"#,##0.00_);[RED]"($"#,##0.00\);6_(\$* #,##0.00_);_(\$* \(#,##0.00\);_(\$* \-??_);_(@_)#\(#,##0.00_);[RED]\(#,##0.00\)                + ) , *   ( (8  (  $  $         (  $ (8  $   ( ` ]lm"6egeneral and administrative$igeneral and administrative-1$ngeneral and administrative-2sbalance sheets }statements of operations"statements of stockholdersstatement of cash flows!hnet income loss per share#net income loss per share-1#net income loss per share-2#net income loss per share-3#tnet income loss per share-4 3 property and equipment4 intangible assetsh4 intangible assets-15 accrued expenses"6 common stock purchase wa$6 common stock purchase wa-1$6 common stock purchase wa-2$6 common stock purchase wa-3"7 share based compensation#Hrestricted stock units rsus stock optionsstock options-1stock options-2"j9 commitments and contingeF10 income taxes10 income taxes-1>10 income taxes-210 income taxes-3"section 302 of the sarbane$ section 302 of the sarbane-1$L section 302 of the sarbane-2$section 302 of the sarbane-3"as adopted pursuant to sec$Zas adopted pursuant to sec-1Tzr8&%%      !"#$%3  @@   Y|LmYears Ended October 31,Increase (Decrease)20192018$%HPV-associated cancers(198)%(Personalized neoantigen-directed therapyHotspot/Off-the-Shelf therapiesProstate cancerOther expensesPartner reimbursements-$Total research & development expense-114%MStock-based compensation expense included in research and development expense-174%#General and Administrative Expenses"General and administrative expense(60OStock-based compensation expense included in general and administrative expense(329TAmendment No. 1, dated as of March 26, 2007, to the License Agreement, between the Trustees of the University of Pennsylvania and Advaxis, Inc. dated as of June 17, 2002, as amended and restated on February 13, 2007. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.WAmendment No. 3, dated as of December 12, 2011, to the License Agreement, between the Trustees of the University of Pennsylvania and Advaxis, Inc. dated as of June 17, 2002, as amended and restated on February 13, 2007. Incorporated by reference to Exhibit 10.5 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.Amendment No. 1 to 2011 Omnibus Incentive Plan of registrant. Incorporated by reference to Annex B to DEF 14A Proxy Statement filed with the SEC on July 19, 2012.Indemnification Agreement. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on August 20, 2013. 10.12 ! Employment Agreement between Advaxis, Inc. and Robert Petit, dated September 26, 2013. Incorporated by reference to Exhibit 10.70 to Registration Statement on Form S-1/A (File No. 333-188637) filed with the SEC on September 27, 2013.Exclusive License and Technology Transfer Agreement by and between Advaxis, Inc. and Global BioPharma, Inc., dated December 9, 2013. Incorporated by reference to Exhibit 10.79 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.10.14! Amendment No. 1, dated as of December 19, 2013, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.82 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.Distribution and Supply Agreement, dated as of January 20, 2014, by and between Advaxis, Inc. and Biocon, Limited. Incorporated by reference to Exhibit 10.7 to Quarterly Report on Form 10-Q filed with the SEC on March 17, 2014.Exclusive License Agreement, dated March 19, 2014, by and between Advaxis, Inc. and Aratana Therapeutics, Inc. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.10.17! Amendment No. 2, dated as of June 5, 2014, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.6 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.Clinical Trial Collaboration Agreement, dated July 21, 2014, by and between Advaxis, Inc. and MedImmune, LLC. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014. 5th Amendment to the Amended & Restated License Agreement, dated July 25, 2014, by and between Advaxis, Inc. and University of Pennsylvania. Incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014.Amendment No. 2 to the Advaxis, Inc. 2011 Omnibus Incentive Plan, effective July 9, 2014. Incorporated by reference to Annex A to Current Report on Schedule 14A filed with the SEC on May 20, 2014.Amended and Restated 2011 Omnibus Incentive Plan, dated September 8, 2014. Incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014.Master Services Agreement for Technical Transfer and Clinical Supply, dated February 5, 2014, by and between Advaxis, Inc. and SynCo Bio Partners B.V. Incorporated by reference to Exhibit 10.1 to Current Report to Form 8-K filed with the SEC on February 11, 2014.Clinical Trial Collaboration and Supply Agreement by and between Advaxis, Inc. and Merck & Co. dated August 22, 2014. Incorporated by reference to Exhibit 10.101 to Annual Report on Form 10-K filed with the SEC on January 6, 201510.24! Amendment No. 3, dated as of April 17, 2015, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.6 to Quarterly Report on Form 10-Q filed with the SEC on June 15, 2015.Co-Development and Commercialization Agreement between Advaxis, Inc. and Especificos Stendhal SA de CV dated February 3, 2016. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on February 26, 2016.10.27! Separation Agreement and General Release, dated July 6, 2017, between Advaxis, Inc. and Daniel J. O Connor. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on July 7, 2017.2015 Incentive Plan of registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on April 7, 2015.10.30! 9Employment Agreement between Advaxis, Inc. and Molly Henderson, dated June 6,2018. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on June 6, 2018.Code of Business Conduct and Ethics dated July 9, 2014. Incorporated by reference to Exhibit 14.1 to Current Report on Form 8-K filed with the SEC on July 10, 2014.31.1*bCertification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 200231.2*bCertification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 200232.1*bCertification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 200232.2*bCertification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002 101.INS**XBRL Instance Document 101.SCH**+XBRL Taxonomy Extension Schema Document 101.CAL**9XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF**9XBRL Taxonomy Extension Definitions Linkbase Document 101.LAB**3XBRL Taxonomy Extension Label Linkbase Document 101.PRE**:XBRL Taxonomy Extension Presentation Linkbase DocumentBALANCE SHEETS October 31,ASSETSCurrent assets:Cash and cash equivalentsRestricted cashAccounts receivableDeferred expenses)Prepaid expenses and other current assetsTotal current assets8Property and equipment (net of accumulated depreciation)3Intangible assets (net of accumulated amortization) Other assets Total assets$LIABILITIES AND STOCKHOLDERS EQUITYCurrent liabilities:Accounts payableAccrued expensesDeferred revenueCommon stock warrant liabilityOther current liabilitiesTotal current liabilities(Deferred revenue- net of current portionOther liabilitiesTotal liabilities&Commitments and contingencies  Note 9Stockholders equity:Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2019 and 2018. Liquidation preference of $0 at October 31, 2019 and 2018.Common stock - $0.001 par value; 170,000,000 shares authorized, 50,201,671 and 4,634,189 shares issued and outstanding at October 31, 2019 and 2018.Additional paid-in capitalAccumulated deficitTotal stockho< lders equity*Total liabilities and stockholders equitySTATEMENTS OF OPERATIONSYear Ended October 31,RevenueOperating expenses:!Research and development expenses#General and administrative expensesTotal operating expensesLoss from operationsOther income (expense):Interest income3Net changes in fair value of derivative liabilities/Loss on shares issued in settlement of warrants Other expense"Net loss before income tax benefitIncome tax expenseNet loss,Net loss per common share, basic and dilutedGWeighted average number of common shares outstanding, basic and diluted"STATEMENTS OF STOCKHOLDERS EQUITYPreferred Stock Common StockAdditional Paid-In AccumulatedTotal Shareholders SharesAmountCapitalDeficitEquityBalance at October 31, 2017$-Stock-based compensationFTax withholdings paid related to net share settlement of equity awards&Tax withholdings paid on equity awards<Tax shares sold to pay for tax withholdings on equity awards/Issuance of shares to employees under ESPP Plan ESPP ExpenseAdvaxis at-the-market salesAdvaxis public offeringsNet LossBalance at October 31, 2018Pre-funded warrant exercisesWarrant exercisesWarrant exchangeBalance at October 31, 2019STATEMENT OF CASH FLOWSOPERATING ACTIVITIESKAdjustments to reconcile net loss to net cash used in operating activities:Stock compensation$Employee stock purchase plan expense#Gain on change in value of warrants*Loss on disposal of property and equipment,Loss on write-down of property and equipment Abandonment of intangible assetsDepreciation expense)Amortization expense of intangible assetsNet accretion of premiums+Change in operating assets and liabilities:Accounts ReceivableIncome taxes receivable%Accounts payable and accrued expenses%Net cash used in operating activitiesINVESTING ACTIVITIES-Purchases of short-term investment securities<Proceeds from maturities of short-term investment securities"Purchase of property and equipment0Proceeds from disposal of property and equipmentCost of intangible assets3Net cash (used in) provided by investing activitiesFINANCING ACTIVITIES@Net proceeds of issuance of common stock and pre-funded warrants*Proceeds from employee stock purchase plan/Employee tax withholdings paid on equity awardsETax shares sold to pay for employee tax withholdings on equity awards)Net cash provided by financing activitiesENet (decrease) increase in cash, cash equivalents and restricted cash?Cash, cash equivalents and restricted cash at beginning of year9Cash, cash equivalents and restricted cash at end of yearNet Income (Loss) per ShareAs of October 31,Warrants Stock optionsRestricted stock unitsTotalDImpact of ASC 606 Adoption on Balance Sheet as of November 1, 2018(in thousands)As reported under ASC 606 Adjustments$Balances without adoption of ASC 606DImpact of ASC 606 Adoption on Balance Sheet as of October 31, 2019[Impact of ASC 606 Adoption on Statement of Operations for the Year Ended October 31, 2019As reported under ASC 606!Research and Development Expenses[Impact of ASC 606 Adoption on Statement of Cash Flows for the Year Ended October 31, 20193. PROPERTY AND EQUIPMENTLeasehold improvementsLaboratory equipmentFurniture and fixturesComputer equipmentConstruction in progressTotal property and equipment)Accumulated depreciation and amortizationNet property and equipment4. INTANGIBLE ASSETSPatentsLicenseSoftwareTotal intangiblesAccumulated amortizationNet intangible assets20202021202220232024 Thereafter5. ACCRUED EXPENSES:Salaries and other compensationVendorsProfessional feesTotal accrued expenses76. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITYExercise Price$Number of Shares Underlying WarrantsExpiration DateSummary of Warrants July 2024July 2019 Public OfferingN/AOther WarrantsSeptember 2024September 2018 Public Offering Grand Total March 2019+March 2014 Public Offering- Placement Agent!Weighted Average Exercise Price8Weighted Average Remaining Contractual Life In YearsAggregate Intrinsic Value8Outstanding and exercisable warrants at October 31, 2017IssuedExpired8Outstanding and exercisable warrants at October 31, 2018 Exercised * Exchanged8Outstanding and exercisable warrants at October 31, 2019October 31, 2019October 31, 2018Exercise Price Stock Price Expected Term 4.87 years 5.87 years Volatility %100.99%97.47%Risk Free Rate1.51%3.03%7. SHARE BASED COMPENSATIONResearch and developmentGeneral and administrativeRestricted Stock Units (RSUs)Number of RSU s'Weighted-Average Grant Date Fair ValueUnvested as of October 31, 2017GrantedVested CancelledUnvested as of October 31, 2018Unvested as of October 31, 2019 Stock Options"Outstanding as of October 31, 2017Cancelled or expired"Outstanding as of October 31, 2018"Outstanding as of October 31, 2019*Vested and exercisable at October 31, 2019Options OutstandingOptions ExercisableWeightedAverageExerciseNumber Remaining IntrinsicPrice Range Outstanding ContractualPriceValue Exercisable $.30-$10.00$10.01-$100.00$100.01-$200.00$200.01-$318.75Year EndedOctober 31, 2019October 31, 20182Weighted average fair value of options granted Expected term5.50-6.51 years5.35-6.51 yearsExpected volatility90.24%-104.99%91.14%-100.34%Expected dividends0%Risk free interest rate 1.35%-3.15% 1.81%-3.16% 9. COMMITMENTS AND CONTINGENCIESYear ended October 31,10. INCOME TAXESFederalCurrentDeferredState and LocalChange in valuation allowanceIncome tax provision (benefit) Years EndedDeferred Tax AssetsNet operating loss carryovers Research and development creditsCapitalized R&D costsOther deferred tax assetsTotal deferred tax assetsValuation allowance.Deferred tax asset, net of valuation allowanceDeferred Tax LiabilitiesOther deferred tax liabilitiesTotal deferred tax liabilities"Net deferred tax asset (liability)US Federal statutory rate21.00%23.17%(State income tax, net of federal benefitPermanent differencesTax Cuts and Jobs ActOtherIncome tax (provision) benefit0.00%Beginning balanceIssuance of warrants'Shares issued in settlement of warrantsChange in fair valueEnding Balance/(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)iI have reviewed this annual report on Form 10-K for the year ended October 31, 2019 of Advaxis, Inc.;6Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;#Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;PThe registrant s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for th<e registrant and have:(a)zDesigned such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)sDesigned such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the registrant s most recent fiscal quarter (the registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; and+The registrant s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant s auditors and the audit committee of the registrant s board of directors (or persons performing the equivalent functions):All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; andAny fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s internal control over financial reporting.December 20, 2019By:/s/ Kenneth BerlinName:Kenneth BerlinTitle:'President & Chief Executive Officer/s/ Molly HendersonMolly Henderson5Chief Financial Officer, Executive Vice PresidentDAS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Date: December 20, 2019Kenneth Berlin'President & Chief Executive Officer c9 cc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} M} }  } }  }  } } }  } } , @ ,,,,, , , , ,,                 ~ .~ B{~       ~ -~ n$~  f ~ R  ~ V2~ ~  ~   ~ ~ ~ r,~ ~ j  ~  ~ J~ ¾~ :  ~ ~ ~  ~ ֠ ~ *z ~ &   ~ 2~ R,~           PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} O} } } }  , @ ,,,,                 ~ N~ B0~      ~ ~ @~  N        PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } } d} ",,,, , , ,,,,,,,,,,~  ~   ~  ~     (\B$@    ~  !~  " # $~  %~  &ffffff$@ 'Qk$@ (q= ףp$@ )~  *!, !+ !,PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } } d} ,,,, , , ,,,,,,,,,~   - . /~  0 1 2~   3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F GPH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  } *,,,,,,, , , , ,,,,,,,,,,,,,,,, H I   J K L~ ~  M ~ F N ~  O~ $~ b P~ f~ . Q~ 4~  R~ C~ rh S~ ~G~ K T~ ~ b U~ &~  V W X~ B~ :X Y~ Z6~ ` Z ~ E [~ N~ e \~ ~  ]~ F~ be ^ ~  _~ ~  `~ zY~ "U!,#,$,%,&,',(,), !a #b $c $ $ %d~ %~ % &e~ &~ &^ 'f~ '΋~ '^ (g~ (i~ (w )h~ )&)~ ))b ))))PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} G} }  } }  } ,,,,,, , , , ,,,,,,,,,,, i j     k~ RF~ ^ l m~ ֠~ *z n~ N~ B0 o~ "_~ j p~ 2~ V q r~ ~  s~ v(~ "5 t~   u~ ~  v~ :~ ~ w~ ~  x~ r~  yq= ףp~  z~ V3~ "b PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} F} } }  } } }  } }  } }  } }  } , @,,,,, , , , , ,,,,,,,,,,,,,, { |  }  ~               ~  ~~ ~ ~ ~ O ~  2~ m~ m ~ ~  ~ ~  ~ 2~ 2 ~ (~ ~  ~ ~  ~ b~ )~ ) ~ ʁl~  ~ ~  ~ ~    ~  6~ ~ ^~ ^~ w ~  ~ J~ J ~ ~  ~ :~ : ~  .t~ R~ R ~  ~  ~  A~ 6~ 6 ~  C~ J~ ~  ~  L4~ ~ ZU~ ^U ~  œ"~ 6~ *~~ ^~ ~ r~ r   ~   ~ ~ ~ ΋~ d  PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} K} }  } }  } 0,,,,,,, , , , , ,,,,,,,,,,,,,,,,,,  j    x~ r~   ~ J~ m ~ ~  ~ ~  t~   ~ b~  ~   ~ B~ ^ ~ &~ f ~  ~   ~   ~ ~  P~ f~   ~ E T~ J~ ^ ~ ~ z Z~ ^~ > _~ ~  ~ ~ >5   ~ <  ~ . ~ *~  ,!,",$,%,&,',(,),*,+,,,-,.,/, ~ N  !~ !~ ! "~ "J~ " $ %~ %^~~ %:e &~ & & '~ '6 (~ (R~ ( ) )~ ) *~ *~ * +~ +:~ +2 ,~ ,~ ,vd -~ -8~ -^B .~ .~ .~ /~ //~ //B////PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,,     ~ :`~ 9 ~ 5"~ ^% ~ ~  ~ {=~ O"PH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )}   @ @ , ,        N~ ~     P~ .~ ~  .3 R     PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )}   @ @ , ,        N      P~ f ~  f R     PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} !}   @ , , ,        k~ RF~ ~  '  ~ ~ ~  " R     PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )} } }  } }   @ , , ,        N      P~ f ~  fB   PH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )} }  } }  }  ,,,,,,, , , , ,  I   ~ ~$~ F$ ~ 65~ V ~  ~  ~ f~ f ~ N~ F ~ m~  ~ ~  ~ C ~ rh B  PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,, , ,  I   ~ &[~ J] ~ & ~ & ~ ~  ~ i~ Bk ~ b~ Z ~ ~G ~ K B  PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } ,,,,,,, ~  ~ j ~ j ~ j ~ j ~ 1 ~ ~GPH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,,  I   ~ z~  ~ 1~ 29 ~ ~  ~ Z6~ `BPHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } }  } } } } }  , @ , , ,,       ~ z   ~ !w!~ f   !+?!~ ^i    ~ :`2PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } }  } } } } +}   @ , , ,,     ~ !w!~ f   ~ !W!~    ~ !+#!~ 9    ~ 9*PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 8} }  } }  }  } }   @,,,,,,, , ,       ~ B ~ !.!~  s  ~ 9~ +# ~ m~ . ~ 9~ !+#!~  /  ~ " ~ zz ~ ~ ~ j ~ :`~ !# !~ s~ V R    PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } ,,,,,,   ~ !!~ !+#! ~ !!~ !# !         2PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } ,,,,,,  j   ~ 2~ R,  ~ ~ @ ~ J~ mBPH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  , @,,,,, , , ,        ~ ڋ~ !+! ~  ~ /. ~ >~  ~ ~~  ~ ~ !n! ~ ~@~ z ~ ~  ~ ~ !kJ !2 PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} *} }  } }  }  } }  , @,,,,, , , ,        ~ ~ !7%!~    ~ > ~ K0 ~ ~ ; ~ ^%~ !߿!~  C  ~ j:~  ~ ~ #. ~ 5"~ !o !~ { ~   ~ >~ ! !~    j      PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } }  } }  } }  }  !!,@!,!,!,!,@!,!,!, !,                                          ! " #  $  % & # $ %  '~ 7~ '~  ! !~ ~ ~  ~ !&!   (~ &O(\!@~  !k. ! ~ 9~  ~ !_5!   )~ 1~ 7~  ! ! ~ ~ ~ !!   * ~ |~ ~ !OJ !  ~ |~ ~ !OJ !  <                    PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 2} } } } } ,@,@,,,,, + , - .~ !!~ !! / 0 1 2 3 4 5 6 6 7 8 9*PHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  }  ,,,,,,, , , , : ;   ~ F ~  ~ f ~  ~ . ~ r ~  * PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,, , , , <   = >   ?~ ~ \ @ >   ?~ z~ ު A~ ~ R B    :  PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} .} }  } }  } ,,,,,,,, , , , ,,,,, C   D E~ a~  ~ ޷~ Ƽ F~ ~ j G~ ^  Z ~ Q H~ V~ . I~  ~ z  J~ *~ * K~ * ~   L M~ ~ Z N~ ~ Z O  z    PHt0(  t>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} (} }  } }  }  ,,,,,,,, , , C   P Q R S~ c~  T~ ~  F~  ~ "k A~ "~ ' U ~ " V~ "[~ "S W X XPHx0(  x>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} '} }  } }  }  ,,,,,,,, j   Y~ e  Z ~  [~   ~ .  \~ ~  ]~ N~ e:PH|0(  |>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,@,@,@ ,@ , , ,,,,@,,, ^~  _~  `~  a~  b   c d e f g h i j~  k  c l e mB  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } '} ,@,,,, n   o #p q r s tPH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,@,@,@ ,@ , , ,,,,@,,, ^~  _~  `~  a~  b   c d e f g h i j~  k  c l e mB  PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } 5} ,@,,,, n  o #u q v s wPH00(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } '} ,,,, x y o #p q z s { PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } 5} ,,,, x y o #u q v s w PHP0(  >@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@Z_@Z_՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFWorkbookCompObjIOle SummaryInformation(DocumentSummaryInformation8h